LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a biotechnology company developing breakthrough therapies for respiratory diseases, today announced that its iSPERSE™ inhaled drug delivery platform demonstrated the capability to formulate a wide range of drugs for inhaled administration, including antibiotics, antibodies and other macromolecules. These preclinical data highlight the ability of iSPERSE formulations to efficiently deliver stable, consistent and therapeutically-relevant drug doses across a broad range of flow rates, offering the potential of improved drug efficacy and safety for patients having both normal and lower or impaired lung function. These results were presented in posters entitled “Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology” and “Development of an iSPERSE™ Based Platform for the Delivery of Macromolecules via Dry Powder Formulations” at Respiratory Drug Delivery 2012, which is being held May 13-17, 2012, in Phoenix, AZ.
